INGELHEIM, Germany, September 03, 2024 – Boehringer Ingelheim today said it has acquired Saiba Animal Health AG, a company focused on the development of novel therapeutic medicines to address chronic diseases in pets.
With the acquisition, Boehringer Ingelheim strengthens its animal health research and development (R&D) pipeline, specifically in the fast-growing pet therapeutics category.
As life expectancy for pets increases, so does the need for effective treatment of debilitating diseases.
Saiba Animal Health's innovative technology platform uses a first-of-its-kind therapeutic vaccine approach, which is designed to create an immune response, targeting chronic diseases such as allergy, inflammation and pain. The therapeutic vaccines incorporate virus-like particles to induce the animal's immune system. They produce neutralizing antibodies against the animal's own disease-causing proteins. This approach may result in a longer duration of action, better treatment outcomes, and increased pet owner convenience and compliance.
“Our pets live longer which creates different needs for their medical care, and often without good existing treatment options”, said Eric Haaksma, Head of Global Innovation, Animal Health at Boehringer Ingelheim. “As a research-driven company, we are very excited about the potential of Saiba Animal Health's groundbreaking technology platform, which could result in a more specific and longer-lasting therapeutic response to chronic diseases in companion animals than current approaches.”
The acquisition follows several development and licensing collaborations between Boehringer Ingelheim and Saiba Animal Health. Those collaborations advanced multiple species-specific product candidates, based on Saiba Animal Health's technology platform, aiming to improve the management of chronic diseases in companion animals.
Dr. Gary T. Jennings, CEO of Saiba Animal Health, said: “We are thrilled that our long-term partnership with Boehringer Ingelheim has evolved to this agreement. Joining forces will pave the way for a whole new class of therapeutic medicines for pets, with a true impact on the lives of animals and their owners.”
Terms of the transaction were not disclosed. Stifel acted as exclusive financial advisor to Saiba Animal Health for the transaction.
Boehringer Ingelheim
Boehringer Ingelheim is a biopharmaceutical company active in both human and animal health. As one of the industry's top investors in Research and Development, the company focuses on developing innovative therapies in areas of high unmet medical need. Independent since its foundation in 1885, Boehringer takes a long-term perspective, embedding sustainability along the entire value chain. More than 53,500 employees serve over 130 markets to build a healthier, more sustainable, and equitable tomorrow. Learn more at www.boehringer-ingelheim.com.
Saiba Animal Health
Saiba Animal Health AG, founded in 2013 as a spin-off from the University of Zurich, Switzerland, has developed a broad and innovative pipeline of Virus-Like Particles (VLP)-based therapeutic vaccines targeting major unmet medical needs in veterinary medicine.
-
中国人寿财险深圳市分公司:以普惠金融 助力家政服务近日,中国人寿财险深圳市分公司与惠州市家政行业协会签订合作协议,旨在通过引入专业的保险保障,促进家政服务业的大力发展,此举亦是普惠金融在家政服务领域的深入2024-09-03
-
Boehringer Ingelheim acquires Saiba Animal Health, adding innovative technology platform to its petINGELHEIM, Germany, September 03, 2024 – Boehringer Ingelheim today said it has acquired Saiba Animal Health AG, a company focused on the developmen2024-09-03
-
品善生物新研发中心启航,助推生物制药工艺创新研发2024年8月29日,上海——品善生物科技(上海)有限公司(简称“品善生物”)宣布新研发中心正式启航。 新研发中心近2000平方米,拥有两层研发空间,将2024-09-03
-
微藻绿碳科技引领健康美业新风尚,中科蓝智产能新突破8月30日,“绿色生物制造与美丽健康产业创新发展大会”在荣成市举办。本次大会由中国海洋湖沼学会藻类学分会、荣成市政府、中国科学院青岛生物能源与过程2024-09-03
-
尼得科精密检测科技将参展IPCA Expo 2024尼得科精密检测科技株式会社将参展2024年9月11日(周三)~9月13日(周五)于印度大诺伊达举办的“IPCA Expo 2024”,该展会是聚焦于印度的电子回路(电子基板、电子安装2024-09-03